Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Late-Stage Pipeline

25%

1 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

Phase 2
2(50.0%)
Phase 4
1(25.0%)
N/A
1(25.0%)
4Total
Phase 2(2)
Phase 4(1)
N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT06435286Phase 2Recruiting

Effectiveness and Performance of an Optical Biopsy Technology for Esophageal Cancer in Brazil and the United States

Role: collaborator

NCT06356012Phase 4Recruiting

Clinical Outcome and Biomarkers for Predicting Immunological Response in Patients Treated with Imiquimod

Role: collaborator

NCT06136702Not ApplicableUnknown

ELEVATE Acceptability Study

Role: collaborator

NCT01859728Phase 2Unknown

GAMBIT Trial: Cisplatin Plus Irinotecan in the Treatment of Gallbladder or Biliary Tract Cancer

Role: lead

All 4 trials loaded